Three privileged scaffolds, one pipeline: chalcones, pyrazolines and pyrazoles in drug discovery and fluorescent sensing
Abstract
Chalcones, pyrazolines, and pyrazoles constitute a uniquely powerful discovery pipeline in which each is a privileged scaffold with distinct applications, while also serving as the synthetic precursor to the next. Despite a theoretical chalcone library exceeding 680 000 unique structures accessible from commercial starting materials alone, fewer than 5140 examples have been reported in the literature-representing just 0.8% of this chemical space. Combining this precursor library with the downstream pyrazoline and pyrazole chemical spaces yields a combined landscape conservatively estimated to exceed 7.5 million unique structures, which remains largely unexplored. This review examines leading examples from 1990 to 2025 across all three scaffold classes, with particular emphasis on the most promising applications of this pipeline: anti-cancer, anti-inflammatory, anti-viral, and fluorescent sensing applications. We explore how pharmacophore hybridisation is further expanding this pipeline. Whereas previous reviews have focused on individual scaffold classes in isolation, this review takes an integrated, systematic approach that unifies all three into a single coherent discovery pipeline. We conclude with a roadmap on how the convergence of design of experiments, automated synthesis, high-throughput screening, and machine learning will unlock the potential of this vastly unexplored chemical space.
How strong is the evidence?
Evidence Hub reads this as a review, done in computer models (in silico), not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
- Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease
- Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience
- Celecoxib or naproxen treatment does not benefit depressive symptoms in persons aged 70 and over: findings from a randomized controlled trial
- Comparative Clinical Effectiveness of Nonsurgical Treatment Methods in Patients With Lumbar Spinal Stenosis: A Randomized Clinical Trial
- Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.